Highlights Mangalam Drugs & Organics Limited

Equities

MANGALAM

INE584F01014

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 05:00:45 2026-02-06 am EST			5-day change	1st Jan Change
35.54 ^INR	+3.58%		-2.07%	+28.81%

Feb. 06	Mangalam Drugs and Organics names Jeevan M. Dalvi as CFO	RE
Jan. 17	Mangalam Drugs and Organics Limited Announces Resignation of Rukmesh P. Dhandhania as Independent Director and Member of Audit and Nomination and Remuneration Committees, Effective January 16, 2026	CI

Highlights

Jan. 15	Mangalam Drugs & Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
Nov. 25	Mangalam Drugs and Organics gets order worth 150 million rupees	RE
Nov. 25	Mangalam Drugs and Organics Limited Receives Significant Repeat Export Order for Anti-Malarial API from One of Its Reputed International Clients	CI
Nov. 20	Mangalam Drugs & Organics Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025	CI
25-08-22	Mangalam Drugs & Organics Secures Export Order Worth Over $2 Million; Shares Jump 4%	MT
25-08-22	Mangalam Drugs & Organics Limited Receives Significant Repeat Export Order from One of Its Reputed International Clients	CI
25-08-07	Mangalam Drugs & Organics Limited Reports Earnings Results for the First Quarter Ended June 30, 2025	CI
25-05-17	Mangalam Drugs & Organics Limited Reports Earnings Results for the Full Year Ended March 31, 2025	CI
25-02-13	Mangalam Drugs & Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024	CI
24-11-14	Mangalam Drugs & Organics Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024	CI
24-08-26	Mangalam Drugs Secures R&D Grant for Anti-Malaria Drug; Shares Jump 7%	MT
24-08-20	Mangalam Drugs & Organics Introduces New Malaria Treatment Drug; Shares Up 7%	MT
24-08-20	Mangalam Drugs & Organics Limited Announces Expanding Its Anti-Malaria API Portfolio with the Introduction of Pyronaridine	CI
24-08-13	Mangalam Drugs & Organics Limited Reports Earnings Results for the First Quarter Ended June 30, 2024	CI
24-03-15	Mangalam Drugs & Organics Limited agreed to acquire Shri JB Pharma LLP.	CI
24-02-13	Mangalam Drugs & Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
23-11-08	Mangalam Drugs & Organics Limited Reports Earnings Results for the Half Year Ended September 30, 2023	CI
23-08-10	Mangalam Drugs & Organics Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	CI
23-05-30	Mangalam Drugs & Organics Limited Reports Earnings Results for the Full Year Ended March 31, 2023	CI
23-05-30	Mangalam Drugs & Organics Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	CI
23-02-13	Mangalam Drugs & Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	CI
22-11-11	Mangalam Drugs & Organics Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	CI
22-08-05	Mangalam Drugs & Organics Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	CI
22-05-27	Mangalam Drugs & Organics Limited Reports Earnings Results for the Full Year Ended March 31, 2022	CI
22-05-26	Mangalam Drugs & Organics Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights Mangalam Drugs & Organics Limited

Equities

MANGALAM

INE584F01014

Pharmaceuticals

Highlights

Filters